Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c combined with furmonertinib or liposomal irinotecan in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
CTR20243266Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Sep 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DP303c, furmonertinib, nanoliposomal irinotecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Shanghai Institute of Materia Medica. Started Sep 2024; status: active.
02
Drugs
DP303cfurmonertinibnanoliposomal irinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20243266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243266.